Related Experiment Videos
Immunoprophylaxis of infections with respiratory syncytial virus: observations and hypothesis
1Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799.
Insights
Intravenous immunoglobulin (IVIG) reduced respiratory syncytial virus (RSV) replication in animal models and human infants. This suggests IVIG may be a promising therapy for preventing serious RSV infections in high-risk infants.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Respiratory syncytial virus (RSV) causes significant illness and death in infants, particularly premature infants or those with underlying health conditions.
- Humoral immunity was historically underestimated for its role in preventing or treating lower respiratory tract RSV infections.
Purpose of the Study:
- To investigate the role of humoral immunity in preventing and recovering from RSV infections.
- To evaluate the efficacy of intravenous immunoglobulin (IVIG) for prophylaxis and treatment of RSV infections.
Main Methods:
- Experiments were conducted in RSV-infected cotton rats, owl monkeys, and human infants.
- Studies utilized IVIG administered parenterally or topically for prophylaxis or treatment.
- RSV replication titers and RSV-neutralizing antibody titers were measured.
Main Results:
- Prophylactic and therapeutic administration of IVIG significantly reduced RSV replication in all tested models.
- Reductions in viral titers positively correlated with levels of RSV-neutralizing antibodies.
- IVIG demonstrated potential for both preventing and treating RSV infections.
Conclusions:
- Humoral immunity, specifically through RSV-neutralizing antibodies found in IVIG, plays a crucial role in controlling RSV infections.
- Parenteral IVIG prophylaxis warrants further clinical investigation for preventing severe RSV disease in high-risk infants.
Abstract:
Infections with respiratory syncytial virus (RSV) may cause substantial morbidity and increased mortality in neonates and infants, especially those born before term and/or with pulmonary or cardiac disease. Humoral immunity was long thought to play only a small role in prevention, reduction of severity, or recovery from RSV infections of the lower respiratory tract. We recently performed a series of experiments in RSV-infected cotton rats, owl monkeys, and human infants to assess the role of humoral immunity in the prevention or recovery from RSV infections. This report summarizes studies utilizing intravenous IgG (IVIG) administered parenterally or topically (into the lower airway) for prophylaxis or treatment of RSV infections of the lower respiratory tract. The prophylactic administration (parenteral or topical) of IVIG to cotton rats or its therapeutic administration to RSV-infected cotton rats, owl monkeys, or humans significantly reduced RSV replication. The reductions in titers of virus correlated positively with titers of RSV-neutralizing antibody. Clinical trials are indicated to determine whether parenteral IVIG prophylaxis might prevent serious RSV infections in high-risk infants.